# Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.

> **NCT03212131** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 34 (actual)

## Conditions studied

- Growth Hormone Disorder
- Adult Growth Hormone Deficiency
- Growth Hormone Deficiency in Children

## Interventions

- **DRUG:** Somapacitan

## Key facts

- **NCT ID:** NCT03212131
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-16
- **Primary completion:** 2018-03-08
- **Final completion:** 2018-03-08
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2019-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03212131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03212131, "Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03212131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*